Thank you, Sabina, and good morning from Boston here in the US, where I'm attending the annual conference for solid organs focusing on heart and lung.
Together with Thermo Fisher. And what a great week in Boston.
This already is. I can tell you Q1 of 2025 was, as mentioned.
Our second-best revenue quarter in the history of the company.
Despite the expected softness in revenues from Thermo Fisher, we advanced our business on many fronts, launched our new strategy, optimized our cost structure, and most importantly, we continued to onboard more new customers, which I will update you on here in the coming slides. Moving up and updating you on Thermo Fisher. Q1 was decent even despite the very strong Q4 of last year, including the stock-up effects mentioned for Thermo Fisher on their side. We continue to win over large new accounts, as Fredrik also mentioned in his slides earlier. And generally, we see Thermo Fisher drive the market expansion in a very strong manner across both Europe and North America, while gradually establishing the business outside these territories.
And I've had many potential customers here at this conference outside Europe and North America coming to us and asking how they can get started with testing cfDNA. So it's a very promising outlook.
The FDA program continues to follow the plan, and we are engaging with several clinical sites within the US to assist us, along with the studies needed for the FDA application as communicated.
This is basically only about replicating data that we have from Europe already.
We know that the product works well, and hence this is not a question of if, but it's only a matter of when the FDA approval will come.
A general update on North America.
As Fredrik mentioned, within our lab, we are soon planning on submitting our reimbursement application to MolDx related to our transplant.
Transplant Trace cfDNA test for solid organs. Reimbursement is expected during the second half of 2025 and is an important milestone that will be instrumental in the current conversations we are having with potential partners within the US about commercializing the services for solid organs. We have also already submitted for reimbursement for our HD service in our Atlanta based Clear Lab, and await confirmation during Q3.
The new Cyted contracts are being delivered on, and there is a lot of activity every week, which we anticipate will only ramp up continuously during the months ahead of us. Art, Dean Canada is starting to generate revenues with Canadian Blood Services, especially as they start testing in larger volumes, while Héma-Québec is expected to reach this a little later on within the US. We continue our work with RDI across different channels, and I remain confident that we're still only at the very onset of our RDI success story here in the States. During Q1, we hosted a US-focused webinar on RDI together with the prestigious CAP Today, featuring two talks from Canadian Blood Services and Héma-Québec in Canada, which generated a lot of interest. And during this year, we will announce more about whom we will be partnering with to conduct RDI testing in the US prior to the prophylactic treatment, as is the current standard. Lastly, we're now starting to see our first customers using our test for cystic fibrosis in clinical routine testing, which is also very promising. Generally, our growth in the US will come from across our product technology areas. Both PCR, next-generation sequencing, and fragment analysis will be accelerated by our clear lab. Moving on to Europe, I'm pleased to see that across our markets in Spain, France, and the UK, we actually had growth of around 50% versus Q1 of 2020. We were impacted by some large customers placing their orders in late Q4 of last year, which affected and softened Q1 of this year. As Sabina has mentioned, the underlying growth and the outlook, however, look strong.
Also in these markets, and as you may have seen, we announced another very strong tender win in Italy just last week with an incremental growth of 10% over the previous tender.
Generally, across Europe in Q1, we had 10% more buying customers than the same period last year, and the average selling prices, excluding transplantation, were 13% above last year as well. Devyser is leading across Europe when it comes to IVD certified products, which is a quality reassurance to our customers that we are the safe choice when considering new products for their labs.
The new IVDR regulation comes into full effect in just a couple of years now, and hence Devyser is in a very strong position to leverage the regulatory leadership that we already have.
Q1 was indeed a busy quarter where we especially focused on the launch of the new strategy.
That was a key milestone.
We are already, for many labs, a preferred one-stop shop, and I'm confident that this is a position we can claim across all our direct markets over time. We're now gearing up to launch several new products and software solutions alongside our collaborations during the remainder of the year, which will further support our growth. As an example, when looking at our four most recent product launches, they accounted for approximately 18% of total revenues in the past year. And with that, I pass the word back to you, Fredrik.